Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)

SHA:605199 Revenue

Hainan Huluwa Pharmaceutical Group had revenue of 153.38M CNY in the quarter ending September 30, 2026, a decrease of -12.38%. This brings the company's total for the last twelve months to 612.37M, down -42.43% year-over-year. In the year 2025, Hainan Huluwa Pharmaceutical Group had annual revenue of 900.84M, down -36.27%. That makes Hainan Huluwa Pharmaceutical Group the 23,347th largest company in the world by revenue and 4,213th in China.

• Revenue (ttm): 612.37M
• Revenue Growth: -42.43%
• P/S Ratio: 3.46
• Revenue / Employee: 291.19K
• Employees: 2,103
• Market Cap: 2.12B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Respiratory System Medication 562.91M 62.5%
• Digestive System Medicine 139.72M 15.5%
• Systemic Anti-Infectives Drugs 92.11M 10.2%
• Other Medicines 60.75M 6.7%
• Active Pharmaceutical Ingredient (api) 45.34M 5.0%

Fiscal year ended Dec 31, 2025 See the full SHA:605199 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	900.84M	-512.71M	-36.27%
Dec 31, 2024	1.41B	-381.64M	-21.26%
Dec 31, 2023	1.80B	280.14M	18.49%
Dec 31, 2022	1.52B	161.25M	11.91%
Dec 31, 2021	1.35B	192.09M	16.53%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 11, 2026

Data Sources Report a data error